

DAFTAR PUSTAKA

1. Sejarah Singkat Narkoba. Available from:
<http://dedihumas.bnn.go.id/read/section/artikel/2011/10/31/189/sejarah-singkat-narkoba>
2. UNDANG-UNDANG REPUBLIK INDONESIA NOMOR 35 TAHUN 2009
TENTANG NARKOTIK
3. Jangan Coba-Coba Mengonsumsi Jamur Tahi Sapi. Available from:
<http://duniasapi.com/id/produk-sapi/2080-jangan-coba-coba-mengonsumsi-jamur-tai-sapi-.html>
4. Passie, Torsten., Seifert, Juergen., Schneider, Udo and M. Emrich, Hinderk. The Pharmacology of Psilocybin. 2002 [homepage on internet]. Available from:
<http://files.shroomery.org/cms/4529203-pharmacologyofpsilocybin.pdf>
5. Peden NR, Pringle SD, Crooks J. "The problem of psilocybin mushroom abuse". *Human Toxicology* 1 (4). 1982: 417–24.
6. Mack RB. "Phenomenally phunny phungi – psilocybin toxicity". *New Castle Medical Journal* 44 (10). 1983: 639–40.
7. Erowid. Psilocybin Mushrooms. 1997 [homepage on internet]. Available from:
http://www.erowid.org/plants/mushrooms/mushrooms_effects.shtml
8. Horibe M. The effects of psilocybin on EEG and behavior in monkeys. *Act Nerv Sup* 1974;16:40–2.
9. Erowid. Psilocybin Mushrooms. 1997 [homepage on internet]. Available from:
http://www.erowid.org/plants/mushrooms/mushrooms_effects.shtml
10. Horibe M. The effects of psilocybin on EEG and behavior in monkeys. *Act Nerv Sup* 1974;16:40–2.
11. Suara Masyarakat. Available from:
http://www.bnn.go.id/portal/index.php/suara_masyarakat/detail/4583 , humas BNN .
12. Amriel, Reza Indragiri. *Psikologi Kaum Muda Pengguna Narkoba*. Penerbit Salemba Humanika. Jakarta; 2008.
13. Brown, T., dan A. King. *Understanding the Psychological Effects of Steer Drugs*. Mind Publisher; 2004.

14. Cassaruba, Santangelo, Sorbera, and Crescimanno. Microstructural Assessment of Rodent Behavior in the Hole-Board Experimental Assay. *Proceedings of Measuring Behavior 2010 (Eindhoven, The Netherlands, August 24-27, 2010)*.
15. Hawari, Dadang. *Penyalahgunaan dan Ketergantungan NAZA (Narkotika, Alkohol, dan Zat Adiktif)*. Balai Penerbit Fakultas Kedokteran Universitas Indonesia (FKUI). Jakarta; 2003.
16. Narkoba. Available from:
www.bnn.go.id
17. Kuhn, Cynthia; Swartzwelder, Scott and Wilson, Wilkie. Buzzed: The Straight Facts about the Most Used and Abused Drugs from Alcohol to Ecstasy. W.W. Norton & Company Inc. 1998 & 2003; p. 83.
18. Stamets, Paul. *Psilocybin Mushrooms of the World*. Ten Speed Press; 1996.
19. Tsujikawa K, Kanamori T, Iwata Y, Ohmae Y, Sugita R, Inoue H, Kishi T.
Morphological and chemical analysis of magic mushrooms in Japan. *Forensic Science International*; 2003. 138(1-3): 85-90.
20. Erowid. ["Dosage Chart for Psychedelic Mushrooms"](#) (shtml). Erowid. Retrieved; 2006.
21. Passie T, Seifert J, Schneider U, Emrich HM. "The pharmacology of psilocybin; 2002.
22. Lisa Jerome (March-April 2007), [Psilocybin Investigator's Brochure](#)
23. ["Drug profiles: Hallucinogenic mushrooms"](#). European Monitoring Centre for Drugs and Drug Addiction.
24. Matsushima Y, Eguchi F, Kikukawa T, Matsuda T. Historical overview of psychoactive mushrooms. *Inflammation and Regeneration* .2009;29(1):47-58
25. Hofmann A, Heim R, Brack A, Kobel H, Frey A, Ott H, Petrzilka T, Troxler F. "Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen [Psilocybin and psilocin, two psychotropic substances in Mexican magic mushrooms]" (in German). *Helvetica Chimica Acta* 1959; 42 (5).

26. Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX
Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed
5-HT_{2A} and 5-HT_{1A} agonist psilocybin.
Neuropsychopharmacology. 2005; 30. 1154-62.
27. Halberstadt AL, Geyer MA. ["Multiple receptors contribute to the behavioral effects
of indoleamine hallucinogens"](#). *Neuropharmacology* 2011; 61 (3). 364–81
28. Van Amsterdam J, Opperhuizen A, van den Brink W. ["Harm potential of magic
mushroom use: a review"](#). *Regulatory Toxicology and Pharmacology* 2011; 59 (3).
423–9.
29. Diaz, Jaime. *How Drugs Influence Behavior: A Neurobehavioral Approach*,
Englewood Cliffs: Prentice Hall; 1996.
30. Meyer MR, Maurer HH. "Absorption, distribution, metabolism and excretion
pharmacogenomics of drugs of abuse". *Pharmacogenomics* 2011; **12** (2). 215–33
31. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. "Acute psychological
and physiological effects of psilocybin in healthy humans: a double-blind, placebo-
controlled dose-effect study". *Psychopharmacology* 2004; **172** (2). 145–56.
32. Nicholas LG, Ogame K. ["Psilocybin Mushroom Handbook: Easy Indoor and Outdoor
Cultivation"](#). Oakland, California: Quick American Archives. 2006; p. 164.
33. Beck O, Helander A, Karlson-Stiber C, Stephansson N. "Presence of
phenylethylamine in hallucinogenic *Psilocybe* mushroom: possible role in adverse
reactions". *Journal of Analytical Toxicology* 1998; **22** (1). 45–9.
34. van Amsterdam J, Talhout R, Vleeming W, Opperhuizen A. "Contribution of
monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction". *Life
Sciences* 2006; **79** (21). 1969–73.

35. Kysilka R. (1990). "Determination of psilocin in rat urine by high-performance liquid chromatography with electrochemical detection". *Journal of Chromatograph*. 1990; **534**: 287–90.
36. Sticht G, Käferstein H. "[Detection of psilocin in body fluids](#)". *Forensic Science International* 2000; **113** (1): 403–7
37. Adolf R.O. Normal-phase separation effects with lipids on a silver ion high performance liquid chromatography column. *Journal of Chromatography*.1996;764 (1997):337-340
38. World health organization. General guidelines for methodologies on research and evaluation of traditional medicine [homepage on internet]. Geneva: WHO; 2001.
39. Reigner B, Blesch K. Estimating the starting dose for entry into humans: principles and practice. *European Journal of Clinical Pharmacology*. 2002;57(12):835-845.